Standard BioTools Inc expected to post a loss of 21 cents a share - Earnings Preview

Standard BioTools

05/08/2023 03:06

* Standard BioTools Inc  LAB.OQ   LAB.O  is expected to show
a
rise in quarterly revenue when it reports  results on August 8. 
    * The South San Francisco California-based  company is
expected to
report  a 28.9% increase in revenue to $24.2 million from $18.78
million a year ago, according to the estimate from one analyst,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Standard BioTools
Inc is
for a loss of 21 cents per share. 
    * The one available analyst rating on the shares is "buy".  
    * The average consensus recommendation for the advanced
medical
equipment & technology peer group is also "Buy".​
    * Wall Street's median 12-month price target for Standard
BioTools
Inc is $4​, above​ its last closing price of $2.54. ​​​

This summary was machine generated August 5 at 02:06 GMT.  All
figures in US dollars  unless otherwise stated